

Supplementary Table 1: Baseline demographic and clinical characteristics of PD patients stratified by TSPO genotype.				
	LAB (n=34, 8.7%)	MAB (n=176, 44.8%)	HAB (n=183, 46.66%)	P Value
Age (years)	69.5 ± 8.42 (42-81.6)	69.8 ± 10 (37-89.6)	68.1 ± 9.25 (40.4-96.4)	0.086
Sex (% male)	70.6	63.6	55.2	0.116
Time from diagnosis (years)	0.213 ± 0.218 (0-0.917)	0.247 ± 0.344 (0-2.35)	0.278 ± 0.371 (0-1.88)	0.908
MMSE	28.4 ± 1.37 (24-30)	28.5 ± 1.52 (22-30)	28.4 ± 1.44 (24-30)	0.652
MDS-UPDRS Part III	31.6 ± 12.8 (9-59.3)	31.9 ± 12.9 (7-71.9)	30.8 ± 12.7 (5-67)	0.663
BDI	6.97 ± 4.79 (0-20)	7.65 ± 5.39 (0-26)	7.25 ± 5.92 (0-28)	0.474
LEDD	177 ± 203 (0-840)	145 ± 181 (0-960)	146 ± 192 (0-1040)	0.453
CIRS score	2.12 ± 1.77 (0-7)	2.08 ± 1.49 (0-6)	2.03 ± 1.41 (0-6)	0.919
ACE-R*	91.4 ± 5.35 (79-98)	89.7 ± 6.36 (70-99)	90.4 ± 6.01 (73-100)	0.652
Values shown as mean ± standard deviation (SD) (minimum and maximum values). Group means were compared using Kruskal Wallis tests. LAB- Low affinity binders; MAB - mixed affinity binders; HAB - high affinity binders; MMSE- Mini Mental State Examination; MDS-UPDRS – Movement Disorder Society Unified Parkinson's Disease Rating Scale; BDI – Beck Depression Scale; LEDD – Levodopa equivalent daily dose, ACE-R – Addenbrookes Cognitive Examination Revised, *PICNICs cohort only, (LAB n=20, MAB n=121, HAB n=115)				

